215 patents
Page 8 of 11
Utility
Inhaler
1 Jul 21
There is disclosed an inhaler 10 for delivery of a medicament by inhalation.
Rune Ducce
Filed: 15 Oct 20
Utility
Fumarate Salt of 5-((5-METHYL-2-((3,4,5-TRIMETHYLPHENYL)AMINO)PYRIMIDIN-4-YL)AMINO)-BENZO[D]OXAZOL-2(3H)-ONE
1 Jul 21
Håkan SCHULZ, Reed Warren SMITH, JR.
Filed: 20 May 19
Utility
Compositions and Methods for Improved Nucleases
1 Jul 21
The present disclosure provides recombinant Cas9 proteins with a faster degradation rate than wild-type Cas9.
ANNA-LINA CAVALLO
Filed: 6 Sep 19
Utility
Tear Lipocalin Muteins Binding IL-4 R Alpha
1 Jul 21
The present invention relates to novel muteins derived from human tear lipocalin, which bind to IL 4 receptor alpha.
Andreas HOHLBAUM, Alexandra Baehre, Gabriele Matschiner, Stefan Trentmann, Klaus Kirchfeld, Hans-Juergen Christian
Filed: 16 Dec 20
Utility
JAK1 Selective Inhibitors
24 Jun 21
Karl Magnus NILSSON, Annika Birgitta Margareta ÅSTRAND, Anna Ingrid Kristina BERGGREN, Johan R. JOHANSSON, Matti Juhani LEPISTÖ, Sameer Pralhad KAWATKAR, Qibin SU, Jason Grant KETTLE
Filed: 1 Mar 21
Utility
Combination of EGFR Inhibitor and MEK Inhibitor for use in the treatment of NRAS mutated cancer
17 Jun 21
The invention relates to the methods for identifying resistance to cancer therapy, by identification of an E63K NRAS mutation, a G12V NRAS mutation or a gain of copy number of NRAS gene.
Darren Anthony Edward Cross, Catherine Anne Eberlein
Filed: 16 Dec 20
Utility
Compositions and Methods for Improving the Efficacy of CAS9-BASED Knock-in Strategies
17 Jun 21
The present disclosure provides a non-naturally occurring CRISPR-Cas system comprising: a Cas9 effector protein capable of generating cohesive ends (stiCas9), and a guide polynucleotide that forms a complex with the stiCas9 and comprising a guide sequence, wherein the guide sequence hybridizes with a target sequence in a eukaryotic cell but does not hybridize to a sequence in a bacterial cell, and wherein the complex does not occur in nature.
MARCELLO MARESCA, AMIR TAHERI-GHAHFAROKHI, FREDERIK KARLSSON, MOHAMMAD BOHLOOLY-YEGANEH, LORENZ MARTIN MAYR
Filed: 16 Nov 18
Utility
Chemical Compounds
10 Jun 21
Provided are a series of novel pyridine or pyrimidine derivatives which inhibit CDK9 and may be useful for the treatment of hyperproliferative diseases.
Bernard Barlaam, Christopher De Savi, Janet Hawkins, Alexander Hird, Michelle Lamb, Kurt Pike, Melissa Vasbinder
Filed: 17 Jul 20
Utility
Purinone Compounds and Their Use In Treating Cancer
10 Jun 21
Maurice Raymond Verschoyle FINLAY, Frederick Woolf GOLDBERG, Martin Richard HOWARD, Attilla Kuan Tsuei TING
Filed: 14 Jun 19
Utility
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for the Treatment of Cancer
3 Jun 21
The specification relates to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for use in the treatment of cancer, wherein the EGFR TKI is administered in combination with AZD2811.
Nicolas Floch, Paul David Smith, Matthew Joseph Martin
Filed: 11 Nov 20
Utility
Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer
20 May 21
Bernard Christophe Barlaam, Kurt Gordon Pike, Andrew John Eatherton, Thomas Anthony Hunt
Filed: 1 Dec 20
Utility
Methods for Preventing or Treating Certain Disorders by Inhibiting Binding of IL-4 And/or IL-13 to Their Respective Receptors
20 May 21
The present disclosure relates to methods of treating, ameliorating or preventing a disorder comprising administering a therapeutically effective amount of a composition comprising a protein which inhibits the ligand of Uniprot #P05112 and/or the ligand of Uniprot #P35225 from binding to their respective receptors to a subject in need thereof.
Andreas HOHLBAUM, Laurent Audoly, Beverly Koller
Filed: 5 Nov 20
Utility
Selecting Patients for Therapy with Adenosine Signaling Inhibitors
13 May 21
Described herein are measures of the relative expression levels, within a given sample from a subject, of an ACPP transmembrane splice variant to the expression level of one or more ACPP non-transmembrane splice variant(s).
Bolan LINGHU, Melinda MERCHANT, Kris SACHSENMEIER, Mingchao XIE, I
Filed: 23 Apr 19
Utility
Novel Biomarkers and Methods of Treating Cancer
6 May 21
Biomarkers for the treatment of pathological conditions associated with the PI3K pathway, such as cancer, and methods of using inhibitors of upstream components of the PI3K pathway, such as PI3K-α inhibitors or AKT inhibitors, are described.
Alvaro AVIVAR VALDERAS, Francisco Humberto CRUZALEGUI, Kevin HUDSON, Robert Kenneth McEWEN
Filed: 16 Sep 16
Utility
2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE Compounds
6 May 21
The present invention relates to certain 2-(2,4,5-substituted-anilino)pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exon19 deletion activating mutant and the T790M resistance mutant).
Sam BUTTERWORTH, Maurice Raymond Verschoyle FINLAY, Richard Andrew WARD, Heather Marie REDFEARN, Vasantha Krishna KADAMBAR, Chandrasekhara Reddy CHINTAKUNTLA, Andiappan MURUGAN, Claudio Edmundo CHUAQUI
Filed: 12 Nov 20
Utility
Synthesis of MCL-1 Inhibitor
29 Apr 21
Craig Robert STEWART, Simon HARDY, Andrew STARK, Alexander HIRD, Qing YE, Xiaolan ZHENG, Cati FERRAR, Jan KOEK, Debasis HAZRA
Filed: 29 Mar 18
Utility
Improved Process for the Preparation of Osimertinib (AZD9291) or a Salt Thereof, and "AZD9291 Aniline" or a Salt Thereof
29 Apr 21
An improved chemical process for the manufacture of the compound of Formula (I), which is useful, for example, as a late-stage chemical intermediate in the production of osimertinib (AZD9291) and pharmaceutically acceptable salts thereof.
Alistair John BOYD, Alexander TELFORD
Filed: 31 Jan 17
Utility
Pharmaceutical Composition Comprising a Potent Inhibitor of URAT1
22 Apr 21
The present invention relates to pharmaceutical compositions containing 2-((3-(4-cyanonapthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid or a pharmaceutically acceptable salt (hereinafter referred to as the “Agent”), more particularly to orally deliverable compositions containing the Agent; to the use of said compositions as a medicament; and to processes for the preparation of said compositions.
Joanne REILAND WAKEMAN, Colin ROWLINGS, Sha LIU, Gerry BURKE, Christian VON CORSWANT, Christer TANNERGREN, Johan HJÄRTSTAM
Filed: 31 Aug 20
Utility
Topically Applicable Pharmaceutical Preparation
22 Apr 21
A topical pharmaceutical preparation for administering a slightly soluble PDE4 inhibitor is described.
Christina BOLLE, Rudolf LINDER
Filed: 3 Jun 20
Utility
Methods for Treating Late-onset Asthma Using Benralizumab
1 Apr 21
Provided herein are methods of treating patients with late-onset asthma or asthma falling within Severe Asthma Research Program (SARP) clinical cluster 3 or 5 comprising administering to the patient a therapeutically effective amount of the anti-interleukin-5 receptor (IL-5R) antibody, benralizumab, or an antigen-binding fragment thereof.
Ian HIRSCH, Paul NEWBOLD
Filed: 25 Sep 20